In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Atrial Fibrillation (Management of) 2010 and Focused Update (2012)

ESC Clinical Practice Guidelines

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population.

Cardiovascular Pharmacology and Pharmacotherapy
Invasive Electrophysiology and Ablation
Atrial Fibrillation
Guidelines version available to download
Published in2012
ReferenceEuropean Heart Journal (2012) 33, 2719–2747
Published in2010
ReferenceEuropean Heart Journal (2010) 31, 2369–2429
Published in2012
Published in2011
Published in2012
ReferenceTable of Contents
  • PDA
  • Published in2012
    ReferenceDownload the PDA version
    Published in2012
    ReferenceSlides AFIB focused update 2012
    Published in2011
    Reference2010 Guidelines slides on AFIB
    Published in2012
    ReferenceCME Questions AFIB
    Published in2010
    ReferenceAFIB - Additional References
    Published in2011
    ReferenceESC Statement on Dronedarore
    Table of contents: Full Text (ESC Clinical Practice Guidelines)

    Abbreviations and acronyms



    • Epidemiology
    • Mechanisms of atrial fibrillation

    Detection, 'natural' history and acute management

    • Definition
    • Detection
    • "Natural" time course
    • Electrocardiogram techniques to diagnose and monitor atrial fibrillation
    • Types of atrial fibrillation
    • Initial management
    • Clinical follow-up


    Antithrombotic management

    • Risk stratification for stroke and thrombo-embolism
    • Antithrombotic therapy
    • Anticoagulation therapy with vitamin K antagonist vs control
    • Antiplatelet therapy vs control
    • Anticoagulation therapy with vitamin k antagonist vs antiplatelet therapy
    • Other antithrombotic drug regimens
    • Investigational agents
    • Current recommendations for antithrombotic therapy
    • Risk of bleeding
    • Optimal international normalized ratio
    • Special situations
    • paroxymal atrial fibrilllation
    • Perioperative anticoagulation
    • Stable vascular disease
    • ACS and/ or PCI
    • Elective PCI
    • Non-St elevation myocardial infraction
    • Acute ST segment elevation myocardial infarction with primary percutaneous intervention
    • Acute stroke
    • Atrial flutter
    • Cardioversion
    • Tansoesophageal echocardiogram-guided cardioversion
    • Non-pharmacological methods to prevent stroke

    Rate and rhythm management

    • Acute rate and rhythm management
    • Acute rate control
    • Pharmacological conversion
    • "Pill-in-the-pocket" approach
    • Direct current cardioversion

    Long term management

    • Rate and rhythm control
    • long term rate control
    • Parmacological rate control
    • Atrioventricular node abaltation and modification
    • Long term rhythm control
    • Antiarrhythmic drugs to maintain sinus rhythm
    • Left atrial catheter ablation
    • Surgical ablation

    Upstream therapy

    • Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
    • Aldosterone antagosnists
    • Statins
    • Polyunsaturated fatty acids

    Specific population

    • Heart failure
    • Athletes
    • Valvular heart disease
    • Acute coronoray syndromes
    • Diabetes mellitus
    • The elderly
    • Pregnancy
    • Post-operative atrial fibrillation
    • Hyperthyroidism
    • Wolf-Parkinson-White syndrome
    • Hypertrophic cardiomyopathy
    • Pulmonary disease




    Back to top
    European Society
    of Cardiology

    Les Templiers
    2035 Route des Colles
    CS 80179 BIOT
    06903 Sophia Antipolis
    Cedex France